Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome. 1991

E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
Centers for Disease Control, U.S. Department of Health and Human Services, Atlanta, Georgia.

In the spring and summer of 1981, an epidemic of a new illness now referred to as the toxic oil syndrome occurred in central and northwestern Spain, resulting in some 20,000 cases, 12,000 hospital admissions and greater than 300 deaths in the 1st year of the epidemic. The initial onset of illness was usually acute, and patients presented primarily with a respiratory syndrome involving cough, fever, dyspnea, hypoxemia, pulmonary infiltrates and pleural effusions. While approximately 50% of patients recovered from this acute phase of the illness without apparent sequelae, the remaining patients developed an intermediate or chronic phase, or both, of illness involving severe myalgia, eosinophilia, peripheral nerve damage, sclerodermiform skin lesions, sicca syndrome, alopecia and joint contractures, among other findings. Epidemiologic and analytic chemical studies have clearly linked the toxic oil syndrome to the ingestion of oil mixtures containing rapeseed oil denatured with aniline. However, the precise identity of the etiologic agent within this oil has never been determined. Aniline itself did not cause the illness, but the causal agent may be a reaction product of aniline with some oil component. Although many aspects of disease activity in the involved patients have lessened with time, the ultimate consequences of their disease are not clear and are the subject of ongoing study. The recently described eosinophilia-myalgia syndrome in the United States clinically resembles the toxic oil syndrome.

UI MeSH Term Description Entries
D008297 Male Males
D009135 Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE. Muscle Disorders,Myopathies,Myopathic Conditions,Muscle Disorder,Muscular Disease,Myopathic Condition,Myopathy
D010938 Plant Oils Oils derived from plants or plant products. Oils, Plant,Oils, Vegetable,Plant Oil,Vegetable Oil,Vegetable Oils,Oil, Plant,Oil, Vegetable
D011041 Poisoning A condition or physical state produced by the ingestion, injection, inhalation of or exposure to a deleterious agent. Poisonings
D001937 Brassica A plant genus of the family Cruciferae. It contains many species and cultivars used as food including cabbage, cauliflower, broccoli, Brussel sprouts, kale, collard greens, MUSTARD PLANT; (B. alba, B. junica, and B. nigra), turnips (BRASSICA NAPUS) and rapeseed (BRASSICA RAPA). Broccoli,Brussel Sprout,Cabbage,Cauliflower,Collard Green,Kale,Cabbages,Collard Greens
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D004196 Disease Outbreaks Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS. Outbreaks,Infectious Disease Outbreaks,Disease Outbreak,Disease Outbreak, Infectious,Disease Outbreaks, Infectious,Infectious Disease Outbreak,Outbreak, Disease,Outbreak, Infectious Disease,Outbreaks, Disease,Outbreaks, Infectious Disease
D004802 Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs. Eosinophilia, Tropical,Hypereosinophilia,Tropical Eosinophilia,Hypereosinophilias,Tropical Eosinophilias
D005229 Fatty Acids, Monounsaturated Fatty acids which are unsaturated in only one position. Monounsaturated Fatty Acid,Acid, Monounsaturated Fatty,Acids, Monounsaturated Fatty,Fatty Acid, Monounsaturated,Monounsaturated Fatty Acids
D005260 Female Females

Related Publications

E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
January 2001, Ryoikibetsu shokogun shirizu,
E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
November 1993, Current opinion in rheumatology,
E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
November 1995, Current opinion in rheumatology,
E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
November 1994, Current opinion in rheumatology,
E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
December 1992, Current opinion in rheumatology,
E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
October 1993, The Journal of rheumatology,
E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
January 1996, Advances in experimental medicine and biology,
E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
January 1997, The Journal of rheumatology,
E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
August 1993, Mayo Clinic proceedings,
E M Kilbourne, and M Posada de la Paz, and I Abaitua Borda, and M Diez Ruiz-Navarro, and R M Philen, and H Falk
February 1993, Mayo Clinic proceedings,
Copied contents to your clipboard!